Short Summary
Azurity Pharmaceuticals has filed an IPR petition seeking cancellation of claims 1‑3 of Exelixis’s U.S. Pat. 11,298,349 covering oral cabozantinib (L)-malate formulations. The petition alleges anticipation by the earlier Wilson patent and obviousness over Brown, Kubo and Remington, while arguing that discretionary denial factors do not apply.
Detailed Summary
In a petition for inter‑partes review of U.S. Patent 11,298,349, Azurity Pharmaceuticals challenges claims 1‑3 that claim broad oral tablet or capsule formulations of cabozantinib (L)-malate that are essentially free of process by‑products or the impurity 6,7‑dimethoxy‑quinoline‑4‑ol. The challenger asserts two statutory grounds: (1) anticipation under 35 U.S.C. §102 by the earlier Wilson patent, which discloses a species falling within the claimed genus; and (2) obviousness under 35 U.S.C. §103 over Brown in view of Kubo and the Remington textbook, arguing that the combination of known excipients and a one‑step synthetic route would have been obvious. The petition also contends that the claims lack written‑description support for the broad excipient categories and that all Fintiv discretionary factors and the Advanced Bionics test disfavor denial of institution. No settlement or dismissal is indicated, and the proceeding remains at the petition stage awaiting institution.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Azurity Pharmaceuticals, Inc. vs EXELIXIS, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
IKEA Supply AG et al.vsEverlight Electronics Co., Ltd.
IKEA Supply AG has initiated an IPR challenge against Everlight Electronics Co., Ltd.'s LED packaging patents, arguing that the core 'U-shaped' electrode structure is anticipated and obvious in existing prior art.
Samsung Electronics Co., Ltd. et al.vsNetlist, Inc.
The USPTO denied Samsung's request for Director Review of the PTAB’s Final Written Decision in the Netlist IPR, leaving the Board’s ruling unchanged.
Shenzhen Tuozhu Technology Co., Ltd. et al.vsStratasys, Inc. et al.
Stratasys seeks Director Review to vacate the Referral and Institution of an IPR covering its 3D‑printing patent, arguing the PTAB proceeding duplicates a pending Texas court trial and ignores key Fintiv factors. The request cites procedural errors and improper stipulations by the petitioner.
BOE Technology Group Co., Ltd.vsSamsung Display Co., Ltd.
The PTAB held that Samsung Display’s OLED pixel‑arrangement patent claims 1,4‑10,13 and 15 are obvious over prior art, while claim 2 remains patentable.
Samsung Electronics Co. Ltd. et al.vsMaxell, Ltd.
Samsung has filed an IPR petition challenging Maxell’s 8,471,950 camera‑control patent, asserting that three earlier imaging patents render all 15 claims obvious under 35 U.S.C. §103.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.